Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 270, Issue 1 33-1, 1996, Pages

  Kelley, Shannon R ^a   Kamal, Toheed Jan ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

dopamine; neuroendocrine; prolactin

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA; DILTIAZEM; DOPAMINE; LEVODOPA; NIFEDIPINE; PROLACTIN; PROTIRELIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VERAPAMIL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GALACTORRHEA; HUMAN; HUMAN EXPERIMENT; HYPERPROLACTINEMIA; HYPOTHALAMUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN RELEASE;

EID: 0030023973     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1996.270.1.e96     Document Type: Article

References (34)

1. Annunziato, L., F. Di Renzo, and A. Amoroso. Release of endogenous dopamine from tuberoinfundibular neurons. Life Sci. 35: 399-407, 1984.
2. Barbarino, A., and L. De Marinis. Calcium antagonists and hormone release. II. Effects of verapamil on basal, gonadotropin-releasing hormone- and thyrotropin-releasing hormone-induced pituitary hormone release in normal subjects. J. Clin. Endocrinol. Metab. 51: 749-753, 1980.
3. 2) agonists and antagonists. J. Pharmacol. Exp. Ther. 241: 27-33, 1987.
4. Cummings, D. M., P. Amadio, Jr., L. Nelson, and J. M. Fitzgerald. The role of calcium channel blockers in the treatment of essential hypertension. Arch. Intern. Med. 151: 250-259, 1991.
5. DeMarinis, L., A. Mancini, S. Minnielli, C. D'Amico, M. L. DiPietro, C. Albini, M. Passieri, I. Liberale, E. Menini, and A. Barbarino. Calcium antagonists and hormone release. V. Effects of a calcium-antagonist (verapamil) on pituitary hormone release in hypersecretory states. Horm. Res. Basel 25: 5-12, 1987.
6. 2- entry blockers on dopamine-induced inhibition of in vitro prolactin secretion. Eur. J. Pharmacol. 146: 201-206, 1988.
7. Fearrington, E. L., C. H. Rand, and J. Rose. Hyperprolactinemia-galactorrhea induced by verapamil. Am. J. Cardiol. 51: 1466-1467, 1983.
8. Fine, S. A., and L. A. Frohman. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J. Clin. Invest. 61: 973-980, 1978.
9. Foreman, M. M., and J. C. Porter. Prolactin augmentation of dopamine and norepinephrine release from superfused medial basal hypothalamic fragments. Endocrinology 108: 800-804, 1981.
10. Gibbs, D. M., and J. D. Neill. Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. Endocrinology 102: 1895-1900, 1978.
11. Gluskin, L. E., B. Strasberg, and J. H. Shah. Verapamil-induced hyperprolactinemia and galactorrhea. Ann. Intern. Med. 95: 66-67, 1981.
12. Ho, K. Y., G. A. Smythe, and L. Lazarus. Normal lactotroph sensitivity to graded low-dose dopamine infusions in pathological hyperprolactinemia. Neuroendocrinology 43: 175-181, 1986.
13. Kamal, T. J., S. R. Kelley, and M. E. Molitch. Verapamil-induced hyperprolactinemia is due to decreased tuberoinfundibular dopamine (TIDA) release. Progr. Annu. Meet. Endocrine Soc. 75th Las Vegas 1993, Abstr. 1285.
14. Kamal, T. J., and M. E. Molitch. Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa and bromocriptine. Am. J. Med. Sci. 304: 289-293, 1992.
15. Kelley, S. O., and M. E. Molitch. Effects of different classes of calcium channel blockers on prolactin (PRL) secretion in humans. Progr. Annu. Meet. Endocrine Soc. 76th Anaheim 1994, Abstr. 512.
16. Kuan, S. I., I. S. Login, A. M. Judd, and R. M. MacLeod. A comparison of the concentration dependent actions of thyrotropin-releasing hormone, angiotensin II, bradykinin, and Lys-bradykinin on cytosolic free calcium dynamics in rat anterior pituitary cells: selective effects of dopamine. Endocrinology 127: 1841-1848, 1990.
17. Langer, G., and E. J. Sachar. Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine. Psychoneuroendocrinology 2: 373-378, 1977.
18. Maestri, E., L. Camellini, G. Rossi, G. Bordonal, G. Bellodi, and A. Gnudi. Effects of five days verapamil administration on serum GH and PRL levels. Horm. Metab. Res. 17: 482, 1985.
19. Molitch, M. E. Prolactin. In: The Pituitary, edited by S. Melmed. Boston, MA: Blackwell Scientific, 1995, p. 136-186.
20. Molitch, M. E., R. H. Goodman, K. D. Post, B. J. Biller, A. C. Moses, L. W. King, Z. T. Feldman, and S. Reichlin. Surgical cure of prolactinoma reverses abnormal prolactin response to carbidopa/L-dopa. J. Clin. Endocrinol. Metab. 55: 1118-1123, 1982.
21. Nielsen-Kudsk, J. E., P. D. Bartels, and J. Dalby. Effects of verapamil on diurnal and thyrotropin-releasing hormone-stimulated prolactin levels in man. J. Clin. Endocrinol. Metab. 70: 1269-1272, 1990.
22. 3H] dopamine release from rat tuberoinfundibular neurons. Neuroendocrinology 50 481-487, 1989.
23. Pickar, D., W. M. Wolkowitz, A. R. Doran, R. Labarca, A. Roy, A. Breier, and P. K. Narang. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch. Gen. Psychiatry 44: 113-118, 1987.
24. Prysor-Jones, R. A., J. J. Silverlight, and J. S. Jenkins. Vasoactive intestinal peptide increases intracellular free calcium in rat and human pituitary tumour cells in vitro. J. Endocrinol. 114: 119-123, 1987.
25. Röjdmark, S., D. E. H. Andersson, and L. Sundblad. Calcium and calcium-antagonistic effects on prolactin and growth hormone responses to thyrotropin-releasing hormone and L-dopa in man. J. Clin. Endocrinol. Metab. 53: 594-598, 1981.
26. 2+ from sequestered intracellular pools is not the primary transduction mechanism causing the initial burst of PRL and TSH secretion induced by TRH in normal rat pituitary cells. Cell Calcium 13: 173-182, 1992.
27. Shull, J. D., and J. Gorski. Regulation of prolactin gene transcription in vivo: interactions between estrogen, pimozide, and α-ergocryptine. Mol. Pharmacol. 37: 215-221, 1989.
28. Spedding, M., S. Fraser, B. Clarke, and L. Patmore. Factors modifying the tissue selectivity of calcium-antagonists. J. Neural Transm. 31, Suppl.: 5-16, 1990.
29. Struthers, A. D., J. A. Millar, G. H. Beastall, W. B. McIntosh, and J. L. Reid. Calcium antagonists and hormone release: effect of nifedipine on luteinizing hormone-releasing hormone and thyrotropin-releasing hormone-induced pituitary hormone release. J. Clin. Endocrinol Metab. 56: 401-404, 1983.
30. Teba, L., S. Smailer, and H. C. Taylor. Effect of nifedipine on TRH stimulation of TSH and PRL release by the pituitary gland. Metab. Clin. Exp. 34: 161-163, 1985.
31. Triggle, D. J. Calcium, calcium channels, and calcium channel antagonists. Can. J. Physiol. Pharmacol. 68: 1474-1481, 1990.
32. Velardo., A., S. Ricci, C. Zironi, M. Pantaleoni, G. Zizzo, A. Badiali, and P. Marrama. Effect of prolonged treatment with diltiazem on pituitary secretion of luteinizing hormone, follicle-stimulating hormone, thyrotropin and prolactin. Horm. Res. Basel 37: 137-140, 1992.
33. Veldhuis, J. D., J. L. C. Borges, C. R. Drake, A. D. Rogol, D. L. Kaiser, and M. O. Thorner. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. J. Clin Endocrinol. Metab. 60: 144-149, 1985
34. 3 and nifedipine on prolactin release in normal man. J. Endocrinol. Invest. 8: 103-106, 1985.